戻る Agenda
Impact and Interventions Related to FDASIA: Increasing Diversity in Clinical Trials
Session Chair(s)
Brenda Jamerson, PHARMD
Center Fellow, Biobehavioral and Social Aspects of Health Disparities
Duke University, United States
Sociological Trends Affecting Minority Participation in US Clinical Trials
Learning Objective : Identify strategies to tailor the informed consent to enhance recruitment and comprehension of diverse populations in clinical trials; Recognize key sociological concepts and trends that affect minority participation in US clinical trials; Discuss the FDA Safety and Innovation Act (FDASIA) and the impact that it will have on the need to recruit diverse clinical subjects.
Speaker(s)
Strategies to Improve Informed Consent to Enhance Comprehension and Recruitment of Ethnically Diverse Populations
Brenda Jamerson, PHARMD
Duke University, United States
Center Fellow, Biobehavioral and Social Aspects of Health Disparities
Understanding the Food and Drug Administration Safety and Innovation Act (FDASIA) and How It Will Impact Minority Recruitment
Almenia K. Garvey, MSC
PAREXEL International, United States
Senior Clinical Feasibility Leader
Sociological Trends Affecting Minority Participation in US Clinical Trials
Rebecca Lynn Budd
Navita Clinical Strategy, United States
Managing Director